vTv Therapeutics (VTVT) Expected to Announce Earnings on Thursday

vTv Therapeutics (NASDAQ:VTVT) is expected to post its results before the market opens on Thursday, March 19th. Analysts expect vTv Therapeutics to post earnings of ($0.98) per share for the quarter.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.51. The firm had revenue of ($0.02) million during the quarter.

vTv Therapeutics Price Performance

Shares of vTv Therapeutics stock opened at $38.13 on Tuesday. vTv Therapeutics has a 1-year low of $14.00 and a 1-year high of $44.00. The company has a market capitalization of $150.23 million, a PE ratio of -11.38 and a beta of 0.44. The business has a 50-day moving average of $35.84 and a 200-day moving average of $29.76.

Hedge Funds Weigh In On vTv Therapeutics

Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. bought a new position in shares of vTv Therapeutics during the fourth quarter valued at approximately $221,000. Geode Capital Management LLC lifted its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the last quarter. Finally, 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics in the 4th quarter worth approximately $731,000. Institutional investors own 17.51% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on VTVT shares. Roth Mkm started coverage on vTv Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating and set a $49.00 price target on shares of vTv Therapeutics in a research report on Wednesday, March 11th. HC Wainwright restated a “buy” rating and issued a $47.00 price target (up from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. Finally, Evercore assumed coverage on shares of vTv Therapeutics in a report on Thursday. They issued an “outperform” rating and a $44.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.